EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Early Experience on Universal Prophylaxis in Infants against Respiratory Syncytial Virus: Facts and Expectations

Antoni Soriano-Arandes, Anna Creus-Costa, Aida Perramon-Malavez, Cristina Andrés, Jorgina Vila, Anna Gatell, Maria Piñana, Pepe Serrano, Alejandra González-Sánchez, Ramon Capdevila, Clara Prats, Pere Soler-Palacin und 1 weitere

Seminars in Respiratory and Critical Care Medicine · 01.02.2025 · 46 (01) · 031-040

DOI: 10.1055/a-2531-0968 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Seminars in Respiratory and Critical Care Medicine, erschienen am 01.02.2025. Verfasst von Antoni Soriano-Arandes und 12 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Infectious Diseases and Immunodeficiencies Unit, Children's Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Antiviral Agents, Respiratory Syncytial Virus Vaccines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Fundació la Marató de TV3.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

During the 2023/24 season, nirsevimab significantly reduced the risk of bronchiolitis and confirmed respiratory syncytial virus (RSV) infections in primary care, hospital, and pediatric intensive care unit admissions among infants aged 0 to 11 months, even in a season with a high community RSV burden, particularly for older infants. These findings are very useful for public health authorities to continue to implement immunization campaigns against RSV in the coming seasons. Moreover, universal immunization against RSV represents a transformative step toward reducing the burden of RSV in infants. With promising evidence from recently published studies, the expectations for a reduction of RSV-associated hospitalizations, alongside the improvement of public health outcomes and equitable access to these measures, are high. However, achieving these goals will require addressing challenges related to vaccine uptake, funding, and RSV surveillance to prompt detect resistances due to mutations of the virus. These interventions need to be integrated into public health strategies because they hold the potential to make a significant impact on infant's health worldwide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsAntiviral AgentsRespiratory Syncytial Virus VaccinesHumansInfantInfant, NewbornHospitalizationPalivizumabRespiratory Syncytial Virus, HumanPublic HealthImmunization Programs

Substanzen

Antiviral AgentsPalivizumabRespiratory Syncytial Virus Vaccines

Autor:innen und Institutionen

  • Pediatric Infectious Diseases and Immunodeficiencies Unit, Children's Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain.
  • Infection and Immunity in Pediatric Patients, Vall d'Hebron Research Institute, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain.
  • Pediatric Hospitalization Unit, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain.
  • Department of Physics, Computational Biology and Complex Systems (BIOCOM-SC) Group, Universitat Politècnica de Catalunya, Barcelona, Catalonia, Spain.
  • Respiratory Viruses Unit, Microbiology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain.
  • Centro de Investigación Biomédica en red de Enfermedades Infecciosas CIBERINFEC, Instituto Carlos III, Madrid, Spain.

Förderung

  • Fundació la Marató de TV3

Zitieren

APA

Soriano-Arandes, A., Creus-Costa, A., Perramon-Malavez, A., Andrés, C., Vila, J., Gatell, A., Piñana, M., Serrano, P., González-Sánchez, A., Capdevila, R., Prats, C., Soler-Palacin, P., & Antón, A. (2025). Early Experience on Universal Prophylaxis in Infants against Respiratory Syncytial Virus: Facts and Expectations. Seminars in Respiratory and Critical Care Medicine, 46(01), 031-040. https://doi.org/10.1055/a-2531-0968

Vancouver

Soriano-Arandes A, Creus-Costa A, Perramon-Malavez A, Andrés C, Vila J, Gatell A, et al. Early Experience on Universal Prophylaxis in Infants against Respiratory Syncytial Virus: Facts and Expectations. Seminars in Respiratory and Critical Care Medicine. 2025;46(01):031-040. doi:10.1055/a-2531-0968

BibTeX
@article{SorianoArandes2025,
  author = {Soriano-Arandes, Antoni and Creus-Costa, Anna and Perramon-Malavez, Aida and Andrés, Cristina and Vila, Jorgina and Gatell, Anna and Piñana, Maria and Serrano, Pepe and González-Sánchez, Alejandra and Capdevila, Ramon and Prats, Clara and Soler-Palacin, Pere and Antón, Andrés},
  title = {Early Experience on Universal Prophylaxis in Infants against Respiratory Syncytial Virus: Facts and Expectations},
  journal = {Seminars in Respiratory and Critical Care Medicine},
  year = {2025},
  volume = {46},
  number = {01},
  pages = {031--040},
  doi = {10.1055/a-2531-0968}
}
Kostenlos starten →